Compare Research Peptides

Select 2 peptides to compare benefits, dosage, administration routes, mechanisms, and side effect profiles side by side.

Peptide 1

Peptide 2

	Cartalax AED Tripeptide Sign up to track	Pancragen Pancreatic Bioregulator Sign up to track
Evidence Grade	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data
Regulatory	Research OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use only	Research OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use only
Category	Khavinson Bioregulators	Khavinson Bioregulators
Key Benefits	•Supports collagen synthesis •Improves joint health •Enhances tissue elasticity •Targets fibroblast function +2 more	•Supports pancreatic function •Regulates insulin synthesis •May improve glucose metabolism •Supports enzymatic activity +2 more
Dosage	10-20 mg (capsule) or 1-3 mg (injectable) mg	10-20 mg mg
Frequency	Daily for 10-20 days	Daily for 10-20 days
Administration	OralSubcutaneous	Oral
Mechanism	Cartalax is a Khavinson bioregulator peptide (tripeptide: Ala-Glu-Asp) that targets cartilage and connective tissue. It supports collagen synthesis, improves joint health, and enhances tissue elasticity.	Pancragen is a Khavinson bioregulator tetrapeptide that regulates insulin synthesis and supports pancreatic function. It may improve glucose metabolism and maintain pancreatic cell health.
Side Effects / Risks	Not specified	Not specified
Research Status	Khavinson bioregulator - Russian research	Khavinson bioregulator - Russian research